Summary & Overview
HCPCS J1561: Immune Globulin (gamunex-c/gammaked) 500 mg
HCPCS Level II code J1561 denotes a 500 mg vial of non-lyophilized immune globulin (gamunex-c/gammaked) for injectable administration. This code matters nationally because immune globulin products are commonly used across multiple specialties for immune deficiency, autoimmune disorders, and select acute indications; they are high-cost biologic therapies with implications for coverage, site-of-care decisions, and prior authorization policies. Key payers considered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of clinical context for J1561, typical sites of service where the product is administered, and payer coverage patterns. The publication summarizes benchmark pricing and utilization metrics where available, highlights relevant policy and reimbursement considerations that affect access and site-of-care choices, and outlines coding nuances tied to product formulation and billing. For elements not provided in the input—such as associated taxonomies, ICD-10 diagnoses, and related codes—the text states that data are not available in the input and omits those details.
Billing Code Overview
HCPCS Level II code J1561 describes an injection of immune globulin (gamunex-c/gammaked), non-lyophilized (liquid), 500 mg. This code represents a biologic immunoglobulin product administered as an injectable infusion or injection for immune support or replacement therapy.
Service Type: Intravenous or subcutaneous immune globulin administration (drug product)
Typical Site of Service: Outpatient infusion center, hospital outpatient department, clinic, or physician office
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 55-year-old patient with primary immunodeficiency presents to an outpatient infusion center for replacement therapy with intravenous immune globulin (IVIG). The ordering clinician documents a need for immune globulin due to documented hypogammaglobulinemia and recurrent sinopulmonary infections. The infusion nurse verifies weight-based dosing, reviews allergy history, obtains baseline vital signs, and starts the infusion of J1561 (immune globulin, 500 mg unit dosing) using an infusion pump. The patient is monitored for infusion-related reactions for the duration of therapy; vital signs are recorded at baseline and periodically. If the patient develops mild infusion-related symptoms, the nurse slows the infusion rate and documents the change. Billing captures the number of 500 mg units administered with J1561, the appropriate place of service for an outpatient infusion center, and any applicable modifiers reflecting billing circumstances (e.g., unlisted service, medical necessity exception, or patient status modifiers). Typical workflow includes order verification, pharmacy preparation of liquid immune globulin (gamunex-c/gammaked), bedside administration, monitoring, and documentation of dose and lot numbers for adverse event tracking.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered |